Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Subscribe To Our Newsletter & Stay Updated